CDK4 and neoplasm: Moreover, CDK4/6 inhibitors and anti-PD-1 combination therapy resulted in enhanced and durable tumor shrinkage9, overall suggesting that T cells might play a nonredundant role in antitumor immunity also in luminal-like BC subtypes.